

AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing with Starting Material

-Global CDMO's Heidelberg Facility Supplies more pDNA material to help address growing needs-

Tokyo, February 9, 2022 – AGC (Headquarters: Tokyo; President: Yoshinori Hirai), a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that its biopharmaceutical CDMO subsidiary, [AGC Biologics](#) (Headquarters: United States), has expanded the partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company's Heidelberg facility.

According to a recent [news release](#) from Pfizer and [BioNTech](#), the companies have started to develop an Omicron-based COVID-19 vaccine with first batches expected to be ready for delivery by end of March 2022.

“We are proud to continue to support BioNTech and supply them with pDNA materials for their vaccine production, as a part of the fight against new pandemic variants,” said AGC Biologics Chief Executive Officer, Patricio Massera. “Our pDNA services are a part of our growing global Cell and Gene Therapy offering that includes the development and manufacturing of cell therapies, viral vectors, and messenger RNA.”

“This type of work is what drives us every day,” says AGC Biologics General Manager, Heidelberg, Dieter Kramer. “We appreciate this opportunity to help make a difference in the lives of people around the world and produce life-saving treatments.”

The AGC Biologics Heidelberg facility has more than 20 years of experience delivering a wide range of programs for customers. The site is the company's Center of Excellence for pDNA production, and a central part of the AGC Biologics global network of cell and gene therapy-focused facilities, with additional locations in Milan, Italy and Longmont, Colorado, USA.

For more information on AGC Biologics' Plasmid DNA offering visit www.agcbio.com/plasmid-dna. To learn more about the company's broader cell and gene therapy services visit www.agcbio.com/cell-therapy.

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients' most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

MEDIA INQUIRIES

Chikako Ogawa, General Manager, Corporate Communications & Investor Relations Division AGC Inc.
(Contact: Nakao; Tel: +81-3-3218-5603; E-mail: info-pr@agc.com)

*Handling of personal information is governed by our privacy policy.